Home › Compare › BRIBF vs ADC

BRIBF vs ADC: Dividend Comparison 2026

BRIBF yields 1062.70% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084463.82M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — BRIBF vs ADC

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + ADC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BRIBF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, BRIBF beats the other by $23,012,056,810,758.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + ADC for your $10,000?

BRIBF: 50%ADC: 50%
100% ADC50/50100% BRIBF
Portfolio after 10yr
$16042232.09M
Annual income
$13,536,504,087,126.08/yr
Blended yield
84.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

BRIBF
No analyst data
Altman Z
19.2
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
ADC buys
0
No recent congressional trades found for BRIBF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFADC
Forward yield1062.70% ✓4.13%
Annual dividend / share$2.00$3.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4% ✓
Portfolio after 10y$32084464.00M ✓$178.9K
Annual income after 10y$27,073,008,093,454.87 ✓$80,797.29
Total dividends collected$31704729.30M ✓$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: BRIBF vs ADC ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrADC PortfolioADC Income/yrGap
1← crossover$116,970$106,269.93$10,990$580.36+$106.0K → BRIBF
2$1,286,876$1,161,718.25$12,301$860.26+$1.27M → BRIBF
3$13,321,776$11,944,818.28$14,104$1,298.62+$13.31M → BRIBF
4$129,817,926$115,563,625.92$16,691$2,008.16+$129.80M → BRIBF
5$1,191,375,681$1,052,470,500.56$20,580$3,205.09+$1191.36M → BRIBF
6$10,301,704,979$9,026,933,000.21$26,754$5,330.02+$10301.68M → BRIBF
7$83,971,400,363$72,948,576,035.34$37,196$9,345.14+$83971.36M → BRIBF
8$645,568,504,677$555,719,106,288.88$56,244$17,523.09+$645568.45M → BRIBF
9$4,683,603,649,023$3,992,845,349,018.69$94,286$35,736.21+$4683603.55M → BRIBF
10$32,084,463,997,910$27,073,008,093,454.87$178,949$80,797.29+$32084463.82M → BRIBF

BRIBF vs ADC: Complete Analysis 2026

BRIBF — Stock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

ADC — REIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this BRIBF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs JEPIBRIBF vs OBRIBF vs KOBRIBF vs MAINBRIBF vs NNNBRIBF vs EPRTBRIBF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.